FDA and CDC Lift Recommended Pause on Johnson & Johnson (Janssen) COVID-19 Vaccine Use Following Thorough Safety Review

Following the pause to investigate the risk of thrombosis and thrombocytopenia in six cases, the two agencies have determined that the available data show a favourable risk benefit profile therefore use of the Janssen COVID-19 vaccine should be resumed in the US.

Source:

US Food and Drug Administration